Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC Class-I
Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC Class-I
复制标题
DOI：
10.1046/j.1525-1373.1999.d01-55.x
复制
发表时间：
1999-05-01
影响因子：
--
通讯作者：
Black, AC
中科院分区：
文献类型：
--
作者：
Young, HE;Steele, TA;Black, AC
每年有数百万人遭受组织损失或终末期器官衰竭。尽管同种异体疗法挽救并改善了无数生命，但它们仍然是不完美的解决方案。这些疗法受到供体严重短缺、长期发病率和死亡率的限制。多种移植、先天性畸形、选择性手术和遗传性疾病都有可能使用自体干细胞作为 HLA 匹配供体组织的来源进行治疗。我们目前的研究旨在表征人类祖细胞和多能细胞的细胞表面簇分化（CD）标记，以帮助分离相对纯化的这些细胞群。这项研究检查了从胎儿、成熟和老年个体中分离的人类多能细胞和祖细胞是否存在 15 种 CD 标记物。对胰岛素和地塞米松的反应显示，细胞分离物由谱系定型祖细胞和谱系未定型多能细胞组成，流式细胞术显示细胞群 CD10、CD13、CD56 和 MHC I 类标记物呈阳性，而 CD3、CD5、CD7、CD11b、CD14、CD15、CD16、CD19、CD25、CD45 和 CD65 呈阴性标记。 Northern 分析显示 CD13 和 CD56 在细胞收获时活跃转录。我们报告了这些人类细胞上 CD10、CD13、CD56 和 MHC I 类细胞表面抗原的首次鉴定。
Each year millions of people suffer tissue loss or end-stage organ failure. While allogeneic therapies have saved and improved countless lives, they remain imperfect solutions. These therapies are limited by critical donor shortages, long-term morbidity, and mortality. A wide variety of transplants, congenital malformations, elective surgeries, and genetic disorders have the potential for treatment with autologous stem cells as a source of HLA-matched donor tissue. Our current research is aimed at characterizing cell surface cluster differentiation (CD) markers on human progenitor and pluripotent cells to aid in isolating comparatively purified populations of these cells. This study examined human pluripotent and progenitor cells isolated from fetal, mature, and geriatric individuals for the possible presence of 15 CD markers. The response to insulin and dexamethasone revealed that the cell isolates were composed of lineage-committed progenitor cells and lineage-uncommitted pluripotent cells, Flow cytometry showed cell populations positive for CD10, CD13, CD56, and MHC Class-I markers and negative for CD3, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD45, and CD65 markers. Northern analysis revealed that CD13 and CD56 were actively transcribed at time of cell harvest. We report the first identification of CD10, CD13, CD56, and MHC Class-I cell surface antigens on these human cells.